Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development of targeted radiotherapeutics for the treatment of central nervous system (CNS) cancers and other rare, difficult-to-treat malignancies. The company operates within the biopharmaceutical and oncology industries, with a strategic emphasis on leveraging radioactive isotopes delivered directly to tumor sites to maximize efficacy while limiting systemic toxicity.
The company’s primary value driver is its proprietary rhenium-based radiotherapeutic platform, most notably Rhenium‑186 NanoLiposome (RNL), which is designed for direct delivery into tumors. Plus Therapeutics serves highly specialized oncology markets, including patients with recurrent glioblastoma and leptomeningeal metastases, conditions with limited effective treatment options. The company traces its origins to Cytori Therapeutics, which transitioned its strategic focus and rebranded as Plus Therapeutics in 2019 to concentrate exclusively on radiopharmaceutical oncology development.
Business Operations
Plus Therapeutics operates as a single operating segment, centered on the research and development of radiotherapeutic drugs. The company does not generate commercial product revenue and is primarily funded through equity financing, grants, and strategic partnerships. Its core operations include preclinical research, clinical trial execution, regulatory engagement, and manufacturing coordination for radiopharmaceutical compounds.
The company controls proprietary nanoliposome drug delivery technology combined with radioactive isotopes, enabling localized radiation therapy. Clinical development activities are conducted through a combination of internal management and collaborations with academic medical centers and contract research organizations. Manufacturing of radioactive materials and clinical supply is handled through specialized third-party partners due to regulatory and safety requirements. Plus Therapeutics conducts its clinical programs primarily in the United States, with additional clinical and regulatory activities supported internationally.
Strategic Position & Investments
Strategically, Plus Therapeutics is focused on advancing its lead asset, Rhenium‑186 NanoLiposome (RNL), through late-stage clinical development for CNS oncology indications. Growth initiatives center on expanding clinical indications for RNL, pursuing regulatory pathways such as orphan drug designation, and optimizing dosing and delivery methods to improve patient outcomes.
The company has also invested in pipeline expansion through earlier-stage programs, including Rhenium‑188 NanoLiposome candidates for solid tumors outside the CNS. Plus Therapeutics does not maintain a broad portfolio of operating subsidiaries or diversified investments, reflecting its strategy as a focused, development-stage biotechnology company. Emerging opportunities include potential partnerships with larger pharmaceutical or nuclear medicine companies to support commercialization and global distribution, though no definitive commercial agreements have been publicly confirmed.
Geographic Footprint
Plus Therapeutics is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is primarily U.S.-based, reflecting the location of its management team, regulatory activities, and primary clinical trials.
Internationally, the company maintains a limited but meaningful presence through clinical research activities and regulatory engagement in Australia, where certain clinical studies have been conducted. Overall, Plus Therapeutics’ geographic reach is concentrated in North America with selective international engagement tied directly to clinical development rather than commercial operations.
Leadership & Governance
Plus Therapeutics is led by a management team with experience in biotechnology development, clinical research, and public company governance. The leadership emphasizes a strategy focused on scientific rigor, capital efficiency, and addressing unmet medical needs in oncology through targeted radiotherapeutics.
Key executives include:
- Marc H. Hedrick, MD – President and Chief Executive Officer
- Karin Fong – Chief Financial Officer
- Scott K. Kerns – Vice President, Clinical Operations
- Nancy L. Hazen – Vice President, Regulatory Affairs
The board of directors provides oversight with a focus on clinical execution, regulatory compliance, and shareholder value creation, consistent with the company’s status as a publicly traded, development-stage biotechnology firm.